Sign in
Active, not recruitingPhase 2

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Miami, Middletown, New York, and Uniondale, United StatesSee the 6 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
103 people enrolled
Started
24 Dec 2020
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Craniotomy
  • Cesium-131 brachytherapy
Record updated
4 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adult patients ≥ 18 years of age who are capable of giving consent
  • Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (>/=95%) resection
  • Karnofsky Performance Status score (KPS) of ≥70
  • Ability to undergo brain MRI with gadolinium

Who cannot take part

  • Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2
  • Previous infection within the operative field, current active systemic infection requiring systemic therapy, or immunodeficiency
  • Urgent surgery required prior to availability of brachytherapy; Intraoperative Exclusion Criterion:
  • Patients will be excluded if intraoperative pathology is not consistent with >/=5% viable metastatic disease
  • Unable to tolerate MRI or CT imaging
  • Pregnancy (patients must have a negative pregnancy test within 30 days of the operation)
  • Women must agree to not breastfeed for at least 12 weeks after the procedure (lactating and discarding in that interval allowable)
  • Diagnosis of leptomeningeal carcinomatosis or >5 additional active or untreated CNS lesions for a total of >6 active lesions
  • Apposition of tumor margin to brainstem or optic apparatus

Where in United States

  • Memorial Sloan Kettering at Basking Ridge (Consent Only)Basking Ridge, United States
  • Memorial Sloan Kettering Commack (Consent only)Commack, United States
  • Baptist Health South FloridaMiami, United States
  • Memorial Sloan Kettering Monmouth (Consent Only)Middletown, United States
  • Memorial Sloan-Kettering Cancer CenterNew York, United States
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale, United States

About the trial

What the trial wants to find out

The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.

The 2 groups in the trial

  • Resection without brachytherapyExisting treatment, for comparison

    Patients will undergo craniotomy.

    Treatment: Craniotomy

  • Resection plus brachytherapyTreatment being tested

    Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.

    Treatment: Craniotomy and Cesium-131 brachytherapy

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 June 2026